SMTI logo

SANARA MEDTECH INC

SMTINASDAQ
πŸ† #3331 by market capEarnings Nov 10US Equity
$182.72β–² $7.67 (+4.20%)
Simulated price
πŸ””
Track SMTI
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 4.2%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$323M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-10.8%
Declining
πŸ“ŠGross Margin
93.0%
High
πŸ’΅FCF Margin
6.4%
Moderate
βš–οΈP/S Ratio
2.9x
Cheap
Otter Score
68
Fair
No chart data available for SMTI.

Trading Snapshot

Day Range
$180.51 – $185.78
52-Week Range
$16.05 – $35.34
Volume
$3.81B
Avg Volume
$2.84B
Shares Outstanding
9.2M
Next Earnings
Nov 1, 2026

Fundamentals Snapshot

Annual Revenue
$103M
Last Q Revenue
$28M
P/E Ratio
β€”
P/S Ratio
2.9x
EPS (TTM)
$-3.70
Dividend Yield
β€”
Dilution (1yr)
+1.1%

Why Investors Own SMTI

  • βœ“High-growth profile β€” revenue up +22.1% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 74% gross margin and 19% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SMTI logo

SANARA MEDTECH INC

SMTI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$103Mβ–² +19.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
90.1%β–Ό βˆ’0.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$9Mβ–Ό βˆ’236.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$2Mβ–Ό βˆ’953.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
8.6Mβ–² +1.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$32Mβ–Ό βˆ’$15M YoY
StockOtter Β· stockotter.space

About SANARA MEDTECH INC

Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
68/100

Analyst Price Target

β“˜
Average Target
$203.56
β–² +11.4% Upside
High Target$255.68
Low Target$183.20
Based on 13 analysts

Latest News & Updates